Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06367075
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-10
Brief Title:
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
The Efficacy and Safety of CadonilimabAK104 With Adriamycin for First-line Treatment of Advanced Soft Tissue Sarcoma a Multicenter Single-arm Phase II Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm multicenter trial of cadonilimab AK104 with adriamycin in patients with first-line advanced soft tissue sarcoma the primary objective is to evaluate objective response rate of cadonilimab with adriamycin
Detailed Description:
In this study the screening period does not exceed 28 days and subjects who are qualified after completion of the screening examination and evaluation entered the treatment period and undergo study treatment and visits as specified in the protocol In particular tumor imaging assessments are performed every 2 cycles during the first 16 cycles thereafter tumor imaging assessments are performed every 4 cycles
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None